Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (561)	6/24/2001 7:02:55 PM
From: BulbaMan	Read Replies (1) \| Respond to of 1833

Tomato: Sorry, but according to the guy at the meeting Glass was short on specifics. Personally, I doubt the tax losses are worth very much and think Glass is just using them as an excuse to stall. What Arena paid for Axiom shares seems to me a decent estimate of what they're worth, valuing KDUS holdings at about $.55 per KDUS share (see my post No. 520 on this board). I doubt Glass believes they're worth much less than that. On the hopeful side, a few years ago I made a substantial profit in a situation similar to KDUS. The major shareholder (a multi-multi-millionaire like Icahn) took a cash-rich company and merged it with a sexy growth company and the stock soared. So, I'm being real patient with KDUS.